Skip to main content

ASND · Ascendis Pharma A/S · Metrics

Track ASND — free
$271.19 -0.54 (-0.20%) At close · Nov 17 Play latest call Q2 2026 earnings call transcript
Market Cap
$17.79B
Shares
65.60M
Volume · Nov 17 586.93K Avg daily vol (3M) 735.38K

ASND metrics

75 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$271.19
Market cap
$17.79B

Price action

23 metrics
Price change (1W)
+5.7%
Price change (30D)
+17.9%
Price change (3M)
+9.0%
Price change (6M)
+14.0%
Price change (YTD)
+27.2%
Price change (1Y)
+25.2%
Trailing year
Price change (5Y)
+75.0%
52-week high
$277.18
52-week low
$196.63
Change from 52-week high
-2.2%
Change from 52-week low
+37.9%
Annualized volatility
38.1%
Annualized volatility (3M)
36.6%
Implied volatility (30D)
45.3%
IV rank (1Y)
29.9
IV percentile (1Y)
48.5
Beta
0.4
RSI (14D)
69.0
Price vs SMA 50
+11.7%
Price vs SMA 200
+12.8%
Avg volume (3M)
735,354
Relative volume
0.8
Average dollar volume
$180.02M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
65.60M

Valuation

12 metrics
P / E (TTM)
17.5
Trailing earnings · reciprocal yield 5.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
12.7×
reciprocal yield 7.9%
P / book
10.5
reciprocal yield 9.6%
FCF yield
—
TTM · current market cap
Buyback yield
1.0%
P / FCF
—
P / operating cash flow
28.6
reciprocal yield 3.5%
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
1.0%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-12

Profitability

9 metrics
Gross margin
91.9%
Operating margin
31.6%
Trailing 12 months
Net margin
72.9%
Gross profit (TTM)
$1.11B
Operating profit (TTM)
$379.75M
Net income (TTM)
$1.02B
Trailing 12 months
Diluted EPS (TTM)
$15.52
FCF margin
—
Effective tax rate
-226.4%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-2.63

Growth

11 metrics
Revenue growth YoY
+73.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.40B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.1%
Year over year · more shares
Revenue CAGR (3Y)
+141.4%
Revenue CAGR (5Y)
+153.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
58.4%
Return on assets
36.1%
Debt / equity
—
Current ratio
2.9
EBITDA (TTM)
$462.44M
Free cash flow (TTM)
—
Quick ratio
2.3
Interest coverage
2.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.09B
Total assets
$2.75B
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$621.28M
Capital expenditures (TTM)
—
R&D (TTM)
$328.79M
SG&A (TTM)
—
Stock compensation (TTM)
$140.67M
R&D / revenue
23.5%
Stock compensation / revenue
10.1%

Ownership (13F)

9 metrics
13F filers
346
13F filer change QoQ
+31
Institutional ownership
104.1%
Conviction holders (share of 13F filers)
4.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+1.7%
Holder tenure
19.3
Price vs estimated holder cost
+30.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.4%

Short interest

3 metrics
Short interest
4.6%
Latest settlement · 5.0 days to cover
Days to cover
5.0d
Short-squeeze score
64 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$872,905
Insider-sentiment score
32 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1612042 CUSIP K08588103 13F (30d) 363 filings 333 filers Visit website Investor relations